2. Cell Cycle/DNA Damage Immunology/Inflammation
  3. Checkpoint Kinase (Chk) IFNAR
  4. Monalizumab

Monalizumab  (Synonyms: IPH2201)

Cat. No.: HY-P99032 Pureza: 99.69%
COA
SDS
Technical Support

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1228763-95-8

Tamaño Precio Stock Cantidad
1 mg En stock
5 mg En stock
10 mg En stock
25 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 5 publication(s) in Google Scholar

Monalizumab Recomendaciones destacadas:

Monalizumab Related Antibodies

Top Publications Citing Use of Products

Ver todos los productos específicos de isoformas Checkpoint Kinase (Chk):

Ver todas las isoformas
Chk1 Chk2 BUBR1

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

NKG2A/CD94
In Vitro

Monalizumab blocks NKG2A and enhances CLL NK-cell mediated cytotoxicity against HLA-E-expressing K562 cells[3].
Monalizumab enhances the Enzalutamide (HY-70002) (10 μM)-induced NK cell activation and killing of prostate cancer cells (LNCaP and 22Rv1)[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Monalizumab Related Antibodies
In Vivo

Monalizumab (50  μg, intratumoral injections, together with 8 millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E+ tumors in immunodeficient mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4]
Dosage: 50 μg, together with 8 millions of activated NK cells
Administration: intratumoral injections
Result: Shows a synergestic antitumor effect.
Enhanced NK-cell killing, and induces lysis of tumor cells.
Ensayo clínico
Gene ID

3821  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Peso molecular

146.3 kDa

No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Monalizumab]
Envío

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.
Pureza y Documentación

Purity: 99.69%

SDS (251 KB)

COA (232 KB) SDS-PAGE (74 KB) SEC-HPLC (182 KB)

Inhibitory Antibodies User Guide (603 KB)
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Monalizumab Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Monalizumab1228763-95-8IPH2201IPH 2201IPH-2201Checkpoint Kinase (Chk)IFNARInterferon-α/β receptorInterferon-alpha/beta receptorCancer immunotherapyCD8 T cellsNK cellsNKG2AInhibitory immune receptorHLA-E/Qa-1head and neck squamous cell carcinomacancer immunotherapyimmune checkpoint inhibitorsrecurrent or metastaticInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Monalizumab
Cat. No.:
HY-P99032
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.